Compare LKQ & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LKQ | SYRE |
|---|---|---|
| Founded | 1998 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Motor Vehicles | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4B | 6.3B |
| IPO Year | 2003 | 2015 |
| Metric | LKQ | SYRE |
|---|---|---|
| Price | $24.56 | $71.20 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 12 |
| Target Price | $42.33 | ★ $85.08 |
| AVG Volume (30 Days) | ★ 3.1M | 933.8K |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.91% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.35 | N/A |
| Revenue | ★ $13,651,000,000.00 | N/A |
| Revenue This Year | $2.18 | N/A |
| Revenue Next Year | $1.71 | N/A |
| P/E Ratio | $10.52 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $24.57 | $13.93 |
| 52 Week High | $40.94 | $78.80 |
| Indicator | LKQ | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 24.05 | 54.33 |
| Support Level | N/A | $67.18 |
| Resistance Level | $32.14 | $76.16 |
| Average True Range (ATR) | 1.21 | 4.27 |
| MACD | -0.53 | -0.94 |
| Stochastic Oscillator | 2.92 | 31.84 |
LKQ Corp is a world-wide distributor of vehicle products, including replacement parts, components and systems used in the repair and maintenance of vehicles, and specialty aftermarket products and accessories to improve the performance, functionality and appearance of vehicles. The company is organized into three operating segments: North America; Europe; and Specialty segment. It derives maximum revenue from Europe Segment. Europe segment is a provider of alternative vehicle replacement and maintenance products in Germany, the United Kingdom, the Benelux region (Belgium, Netherlands, and Luxembourg), Italy, Czech Republic, Austria, Slovakia, France and various other European countries.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.